Journal Article

Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial

Rosso-Fernández, Clara, López-Hernández, Inmaculada, Merino, Vicente, Rodríguez-Baño, Jesús, Pascual, Alvaro, Palacios, Zaira, Sojo-Dorado, Jesús, Barriga, Angel, Camean, Manuel, Lavín-Alconero, Lucía

2015

Overview

Introduction Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is imperative. Although fosfomycin was discovered more than 40 years ago, it was not investigated in accordance with current standards and so is not used in clinical practice except in desperate situations. It is one of the so-called neglected antibiotics of high potential interest for the future. Methods and analysis The main objective of this project is to demonstrate the clinical non-inferiority of intravenous fosfomycin with regard to meropenem for treating bacteraemic urinary tract infections (UTI) caused by ESBL-EC. This is a ‘real practice’ multicentre, open-label, phase III randomised controlled trial, designed to compare the clinical and microbiological efficacy, and safety of intravenous fosfomycin (4 g/6 h) and meropenem (1 g/8 h) as targeted therapy for this infection; a change to oral therapy is permitted after 5 days in both arms, in accordance with predetermined options. The study design follows the latest recommendations for designing trials investigating new options for multidrug-resistant bacteria. Secondary objectives include the study of fosfomycin concentrations in plasma and the impact of both drugs on intestinal colonisation by multidrug-resistant Gram-negative bacilli. Ethics and dissemination Ethical approval was obtained from the Andalusian Coordinating Institutional Review Board (IRB) for Biomedical Research (Referral Ethics Committee), which obtained approval from the local ethics committees at all participating sites in Spain (22 sites). Data will be presented at international conferences and published in peer-reviewed journals. Discussion This project is proposed as an initial step in the investigation of an orphan antimicrobial of low cost with high potential as a therapeutic alternative in common infections such as UTI in selected patients. These results may have a major impact on the use of antibiotics and the development of new projects with this drug, whether as monotherapy or combination therapy. Trial registration number NCT02142751. EudraCT no: 2013-002922-21. Protocol V.1.1 dated 14 March 2014.

• Publisher: BMJ Publishing Group,BMJ Publishing Group LTD
• Subject: Administration, Intravenous / Anti-Bacterial Agents - administration & dosage / Anti-Bacterial Agents - therapeutic use / Antibiotics / Bacteria / beta-Lactamases - biosynthesis / Clinical Protocols / Clinical trials / Drug resistance / Drug Resistance, Multiple, Bacterial / E coli / Escherichia coli - enzymology / Escherichia coli Infections - drug therapy / Escherichia coli Infections - microbiology / Fosfomycin - blood / Fosfomycin - therapeutic use / Gastrointestinal Microbiome - drug effects / Gram-Negative Bacteria - drug effects / Hospitals / Humans / Hypotheses / Infectious Diseases / Informed consent / Intestines - microbiology / Meropenem / Microorganisms / Mortality / Nosocomial infections / Pathogens / Research Design / Thienamycins - therapeutic use / Urinary tract diseases / Urinary tract infections / Urinary Tract Infections - drug therapy / Urinary Tract Infections - microbiology / Urine / Urogenital system